Skip to main content

Advertisement

SpringerLink
Log in

Human B Cell Development and Antibody Production in Humanized NOD/SCID/IL-2Rγnull (NSG) Mice Conditioned by Busulfan

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Background

Busulfan treatment as a chemotherapeutic agent has been considered an alternative approach in xenograft model because it offers a simple, convenient, effective, and less toxic conditioning regimen.

Objective and methods

To investigate busulfan effects on the reconstitution of human immune cells and the generation of immune response to foreign antigens, we generated humanized NOD/SCID/IL-2Rγnull (NSG) mice conditioned either busulfan or total body irradiation (TBI) with hCD34+ CB cells.

Results

Busulfan resulted in a high survival rate and effective reconstitution of human immune cells including B, T, macrophage, and dendritic cells in humanized NSG mice, compared to that of TBI. Moreover, the humanized NSG mice conditioned busulfan showed effective B cell development and thereby the high production of human antibody against immunized antigen.

Conclusion

Humanized mice conditioned by busulfan provide a powerful and versatile tool for studying the entire process of human B-lymphocyte development and for producing specific human antibodies

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7:118–30.

    Article  PubMed  CAS  Google Scholar 

  2. Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity. 2007;26:537–41.

    Article  PubMed  CAS  Google Scholar 

  3. Macchiarini F, Manz MG, Palucka AK, Shultz LD. Humanized mice: are we there yet? J Exp Med. 2005;202:1307–11.

    Article  PubMed  CAS  Google Scholar 

  4. Payne KJ, Crooks GM. Immune-cell lineage commitment: translation from mice to humans. Immunity. 2007;26:674–7.

    Article  PubMed  CAS  Google Scholar 

  5. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006;12:1316–22.

    Article  PubMed  CAS  Google Scholar 

  6. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335:256–9.

    Article  PubMed  CAS  Google Scholar 

  7. Kaneshima H, Namikawa R, McCune JM. Human hematolymphoid cells in SCID mice. Curr Opin Immunol. 1994;6:327–33.

    Article  PubMed  CAS  Google Scholar 

  8. Pflumio F, Izac B, Katz A, Shultz LD, Vainchenker W, Coulombel L. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood. 1996;88:3731–40.

    PubMed  CAS  Google Scholar 

  9. Shultz LD, Lang PA, Christianson SW, Gott B, Lyons B, et al. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol. 2000;164:2496–507.

    PubMed  CAS  Google Scholar 

  10. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol. 1998;103:335–42.

    Article  PubMed  CAS  Google Scholar 

  11. Kollet O, Peled A, Byk T, Ben-Hur H, Greiner D, Shultz L, et al. β2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood. 2000;95:3102–5.

    PubMed  CAS  Google Scholar 

  12. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. NOD/SCID/γ nullc mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175–82.

    Article  PubMed  CAS  Google Scholar 

  13. Hiramatsu H, Nishikomori R, Heike T, Ito M, Kobayashi K, Katamura K, et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γ nullc mice model. Blood. 2003;102:873–80.

    Article  PubMed  CAS  Google Scholar 

  14. Haddow A, Timmis GM. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet. 1953;31:207–8.

    Article  Google Scholar 

  15. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–89.

    PubMed  CAS  Google Scholar 

  16. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice. Blood. 2005;106:1565–73.

    Article  PubMed  CAS  Google Scholar 

  17. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523–36.

    Article  PubMed  CAS  Google Scholar 

  18. Mauch P, Down JD, Warhol M, Hellman S. Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan. Transplantation. 1988;46:205–10.

    Article  PubMed  CAS  Google Scholar 

  19. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol. 1993;21:913–21.

    PubMed  CAS  Google Scholar 

  20. Hsieh MM, Langemeijer S, Wynter A, Phang OA, Kang EM, Tisdale JF. Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts. Exp Hematol. 2007;35:1415–20.

    Article  PubMed  CAS  Google Scholar 

  21. Hayakawa J, Hsieh MM, Uchida N, Phang O, Tisdale JF. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rγ null mice. Stem Cells. 2009;27:175–82.

    Article  PubMed  CAS  Google Scholar 

  22. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5:230–42.

    Article  PubMed  CAS  Google Scholar 

  23. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20:149–57.

    Article  PubMed  CAS  Google Scholar 

  24. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179–91.

    Article  PubMed  Google Scholar 

  25. Tonomura N, Habiro K, Shimizu A, Sykes M, Yang YG. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood. 2008;111:4293–6.

    Article  PubMed  CAS  Google Scholar 

  26. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;8:957–69.

    Article  Google Scholar 

  27. Chen J. Animal models for acquired bone marrow failure syndromes. Clin Med Res. 2005;2:102–8.

    Article  Google Scholar 

  28. Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K, et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman–Diamond syndrome. Bone Marrow Transplant. 2007;39:143–7.

    Article  PubMed  CAS  Google Scholar 

  29. Boyd RL, Caro J, Halka KG, Erslev AJ. Granulopoiesis in long-term culture by marrow from mice with busulfan-induced chronic latent aplasia. Int J Cell Cloning. 1986;4:357–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by Mid-career Researcher Program through NRF grant funded by the MEST (2009-0084573; to K.-Y.L.), the Korea Health 21 R&D Project, Ministry of Health and Welfare (A080568; to S.J.K.), and by Medical Research Foundation of Samsung Biomedical Research Institute (SBRI) grant (C-A6-407-1; to S.J.K.).

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, 440-746, Republic of Korea

    Eunyoung Chun, Miyoung Kim, Seong-Tae Kim & Ki-Young Lee

  2. Department of Molecular Medicine, Sungkyunkwan University School of Medicine, Seoul, 135-710, Republic of Korea

    Bongkum Choi & Sung Joo Kim

  3. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Republic of Korea

    Bongkum Choi & Sung Joo Kim

  4. School of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 440-746, Republic of Korea

    Keejung Yoon

Authors
  1. Bongkum Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eunyoung Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miyoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seong-Tae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keejung Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ki-Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sung Joo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ki-Young Lee or Sung Joo Kim.

Additional information

Bongkum Choi, Eunyoung Chun, and Miyoung Kim are equally contributed to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, B., Chun, E., Kim, M. et al. Human B Cell Development and Antibody Production in Humanized NOD/SCID/IL-2Rγnull (NSG) Mice Conditioned by Busulfan. J Clin Immunol 31, 253–264 (2011). https://doi.org/10.1007/s10875-010-9478-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-010-9478-2

Keywords

Search

Navigation